Minimally Invasive Versus Conventional Aortic Valve Replacement: A Propensity-Matched Study From the UK National Data.

OBJECTIVE: Minimally invasive aortic valve replacement (MIAVR) has been demonstrated as a safe and effective option but remains underused. We aimed to evaluate outcomes of isolated MIAVR compared with conventional aortic valve replacement (CAVR). METHODS: Data from The National Institute for Cardiovascular Outcomes Research (NICOR) were analyzed at seven volunteer centers (2006-2012). Primary outcomes were in-hospital mortality and midterm survival. Secondary outcomes were postoperative length of stay as well as cumulative bypass and cross-clamp times. Propensity modeling with matched cohort analysis was used. RESULTS: Of 307 consecutive MIAVR patients, 151 (49%) were performed during the last 2 years of study with a continued increase in numbers. The 307 MIAVR patients were matched on a 1:1 ratio. In the matched CAVR group, there was no statistically significant difference in in-hospital mortality [MIAVR, 4/307,(1.3%); 95% confidence interval (CI), 0.4%-3.4% vs CAVR, 6/307 (2.0%); 95% CI, 0.8%-4.3%; P = 0.752]. One-year survival rates in the MIAVR and CAVR groups were 94.4% and 94.6%, respectively. There was no statistically significant difference in midterm survival (P = 0.677; hazard ratio, 0.90; 95% CI, 0.56-1.46). Median postoperative length of stay was lower in the MIAVR patients by 1 day (P = 0.009). The mean cumulative bypass time (94.8 vs 91.3 minutes; P = 0.333) and cross-clamp time (74.6 vs 68.4 minutes; P = 0.006) were longer in the MIAVR group; however, this was significant only in the cross-clamp time comparison. CONCLUSIONS: Minimally invasive aortic valve replacement is a safe alternative to CAVR with respect to operative and 1-year mortality and is associated with a shorter postoperative stay. Further studies are required in high-risk (logistic EuroSCORE > 10) patients to define the role of MIAVR.

Celox (chitosan) for haemostasis in massive traumatic bleeding: experience in Afghanistan.

The use of Celox, a chitosan-based haemostatic agent, for the control of massive traumatic bleeding in patients arriving at a ROLE 2 (Enhanced Care) Facility in southwestern Afghanistan is described. Twenty-one soldiers with gunshot wounds were treated with successful haemostasis in 18 at the first application and in three after further applications. Celox is an effective haemostatic agent and a useful adjunct for the treatment of massive traumatic bleeding.

Omni-Stat (Chitosan) arrests bleeding in heparinised subjects in vivo: an experimental study in a model of major peripheral vascular injury.

OBJECTIVE: To explore the effectiveness of Omni-Stat (Chitosan) in a model of major haemorrhage in the presence of clotting dysfunction. METHOD: A total of 12 major femoral artery bleeds in moderately heparinised swine treated with Omni-Stat (Chitosan) were compared with five control bleeds. RESULTS: Haemostasis was successfully achieved at first treatment in 10 of 12 bleeds and at second treatment in the remaining two bleeds. CONCLUSION: The study supports the evidence that Omni-Stat (Chitosan) acts independently of classical clotting pathways and should be effective in patients with clotting dysfunctions, who suffer major haemorrhage. It also suggests the potential for a role in cardiac surgery.

A new hemostatic agent: initial life-saving experience with Celox (chitosan) in cardiothoracic surgery.

Celox (MedTrade Products Ltd, Cheshire, UK) is a proprietary preparation of chitosan, indicated for moderate to severe hemorrhage and currently used for hemostasis in the emergency and military settings. We describe its lifesaving use in 2 patients undergoing cardiothoracic surgery in which conventional techniques had failed.

Modifiable risk factors remain significant causes of medium term mortality after first time Coronary artery bypass grafting.

BACKGROUND: Whilst there is much current data on early outcomes after Coronary artery bypass grafting(CABG), there is relatively little data on medium term outcomes in the current era. The purpose of this study is to present a single surgeon series comprising of all first time CABG patients operated on with the technique of cross clamp fibrillation from Feb-1996 to through to Jan-2003, and to seek risk factors for medium term mortality in these patients. METHODS: Data was collected from Hospital Episode Statistics and departmental patient administration and tracking systems and cross checked using database techniques. Patient outcomes were searched using the National Health Service strategic tracing service. RESULTS: Mean follow up was 5.3 years(0-9.4 years) and was complete for all patients. 30-day survival was 98.4%, 1-year survival 95% and 8-year survival 79%. Cox-regression analysis revealed that several modifiable pre-operative risk factors remain significant predictors of medium term mortality, including Diabetes(Hazard Ratio(HR) 1.73, 95%CI 1.21-2.45), Chromic obstructive pulmonary disease(HR 2.02, 95%CI 1.09-3.72), Peripheral vascular disease(HR 1.68, 95%CI 1.13-2.5), Body mass index>30(HR 1.54, 95%CI 1.08-2.20) and current smoker at operation(HR 1.67, 95%CI 1.03-2.72). However hypertension(HR 1.31, 95%CI 0.95-1.82) and Hypercholestrolaemia(HR 0.81, 95%CI 0.58-1.13) were not predictive which may reflect adequate post-operative control. CONCLUSION: Coronary artery bypass surgery using cross clamp fibrillation is associated with a very low operative mortality. Medium term survival is also good but risk factors such as smoking at operation, Chronic obstructive pulmonary disease, obesity and diabetes negatively impact this survival and should be aggressively treated in the years post-surgery.

Surgical resection of melorheostosis in the ribs.

Melorheostosis is a rare nongenetic developmental anomaly of the cortical bone. We present a 40-year-old woman who was diagnosed with melorheostosis affecting the ribs only. Chronic pain and cosmetic deformity were her presenting symptoms. She underwent posterolateral thoracotomy and excision of the affected ribs, with a satisfactory outcome of this uncommon presentation.

The frequency of pleural effusions after Bellovac drainage following coronary bypass grafting.

BACKGROUND: A common postoperative complication after CABG with internal mammary artery (IMA) harvest is the evolution of a pleural effusion. Our aim was to see if the intra-operative insertion of a Bellovac drain to the pleural cavity, with drainage continuing for 4-days post operation, eliminates the complication of pleural effusion. METHODS: Using our computerised audit database, 500 consecutive patients were identified who had undergone CABG including at least one internal mammary graft by a single consultant at Blackpool Victoria Hospital. All these patients received Bellovac drainage for 4 days on the side of the harvested IMA. The chest X-ray reports were retrospectively collected from the hospital computer databases. The 4-day post-operative, and the 6-week post-operative films were found. In the cases where no consultant radiologist report was found J.D. reviewed the film, and any abnormalities were also reviewed by R.W.J.M. RESULTS: Out of 500 radiographs, six patients (1.2%) died, 25 patients had no traceable record of a chest X-ray, 434 patients had an entirely normal chest X-ray and 461 patients had no effusion at 6 weeks. Six patients had a small effusion at 6 weeks, two had a moderate effusion successfully treated conservatively, and no patients had a pleural effusion that required drainage. CONCLUSION: In patients undergoing coronary arterial bypass grafting with internal mammary artery harvest, the intra-operative insertion of a Bellovac drain on the side of the harvested IMA reduces the risk of postoperative pleural effusions